Moderna's 0.96% Gain on 220M Volume (Rank 482) Driven by Kyoto Conference Debut of Rare Disease mRNA Trials

Moderna (MRNA) rose 0.96% on 9/4/2025 with $220 million in trading volume, ranking 482nd in the market. The stock's performance coincided with the announcement of data to be presented at the 2025 International Congress of Inborn Errors of Metabolism in Kyoto, Japan.

The biotech firm will showcase five abstracts at the event, including three oral presentations and two posters. These cover its mRNA therapies for propionic acidemia, methylmalonic acidemia, and Glycogen Storage Disease Type 1a. This marks Moderna's first presentations on methylmalonic acidemia and GSD1a at a scientific conference.

The presentations include interim data from Phase 1/2 trials and final results from dose-escalation studies. The data may influence investor perceptions of Moderna's pipeline and its potential in treating rare metabolic disorders. The company's focus on mRNA-based solutions for rare diseases aligns with its broader strategy to expand therapeutic applications.

Moderna closed at $24.15, down 0.54% in after-hours trading. The stock gained 0.96% during regular trading hours on September 4, 2025.